Press


BioXcel Therapeutics to Ring the NASDAQ Stock Market Opening Bell on April 20, 2018

BRANFORD, Conn., April 19, 2018 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that the Company will ring The Nasdaq Stock Market Opening Bell at the Nasdaq MarketSite in Times Square on Friday, April 20, 2018.  The bell ringing ceremony will be held in honor of BioXcel Therapeutics’ recent initial public offering (IPO) and listing on the Nasdaq Stock Market.


“We are honored to celebrate our IPO and listing on the Nasdaq Capital Market,” said Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel Therapeutics. “This is truly an exciting time for BioXcel Therapeutics and our lead programs, BXCL501 in neuroscience and BXCL701 in immuno-oncology. The Company is in the midst of a transformative period, with a number of important clinical and operational milestones expected this year and into the future. I would like to thank our employees, investors and partners who have contributed to our achievements thus far. We remain committed to bringing our highly innovative, potentially breakthrough therapies to the market for patients, and creating long-term shareholder value.”

A live webcast of The Nasdaq Stock Market Opening Bell ceremony will be available at
https://livestream.com/nasdaq/live.

About BioXcel Therapeutics, Inc. (BTI):

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Contact Information:
BioXcel Therapeutics
The Ruth Group
Lee Roth
646-536-7012
lroth@theruthgroup.com